Dr. Altschuler has 30 years of academic and industrial R&D experience in cell and molecular biology. He has an in-depth experience and knowledge in the oncology arena which includes the needs, science, clinic, business as well as regulatory and IP issues.  He founded CELL Response to solve the paradigm of cancer drug triggered resistance to targeted therapeutics.  Prior to CELL Response (2011), he has founded and served as the CSO of NovellusDx. NovellusDx developed and operates a novel personalized medicine platform technology to provide the oncologist with the intelligence required to prescribe the correct targeted therapy treatment that the patient will respond too. Prior to NovellusDx, he served as the Chief Scientific Officer of Pri-Ness, which focused on the development of a biologic drug to cure male infertility. Earlier, he was an assistant professor in the Faculty of Medicine, Hebrew University. Conducted his postdoctoral at UCSF, during which he initiated a collaboration with LI-COR to develop a near-infrared scanner that was eventually launched in 2000 and became known as the Odyssey Imaging System.  This is currently a leading device in the lab instrumentation arena.   He hold an M.Sc. and Ph.D. from the Weizmann Institute of Science. He was awarded  The Fienberg Graduate School of the Weizmann Institute Prize for Excellence in Ph.D. studies and The Israeli Parliament Award for Excellence in academic studies. He is the author of over 40 peer-reviewed scientific papers and 3 issued patents.

Dr. Pe’er David is an accomplished life science executive scientist, with over 25 years’ experience in biologics, small molecules, and in vitro diagnostic medical devices. He established and led two pharmaceutical startup companies and managed several drug discovery and development programs from inception to clinical studies. Dr. David has a Ph.D. from the Weizmann Institute of Science and carried out his postdoctoral studies at Yale University.

Olga has 27 years of experience in both the research and clinical setups.  Her diverse research experience is in the Biochemistry, Cell and Molecular biology fields.  During that period she was assigned to be the lab manager of several labs.

An accomplished medicinal chemist with extensive experience ranging from hit identification through drug optimization to final clinical candidates. 25 years of leading medicinal chemistry in early-stage startups provided him with expertise in optimizing physicochemical properties, pharmacokinetics, metabolism, and toxicity (ADMET) of drug candidates. Will resign from his positions and join us following the next funding round.  Currently, he contributes to the company during his off time….  

EE has ample experience in designing and executing cell and molecular assays. Talented, passionate & motivated biologist leading the development of cutting-edge assays for therapeutics. Founded and supervised R&D labs, operating automated high throughput technologies. Will resign from his positions and join us following the next funding round.  Currently, he contributes to the company during his off time….    

Talented data researcher with capabilities to implement data analyses as part of the decision-making process.  He is an expert in artificial intelligence and image processing. In his previous position, he significantly contributed to assay development of a cutting-edge diagnostic platform. Will resign from his positions and join us following the next funding round.  Currently, contribute to the company during his off time….  

Ample expreiance in leading technological startups. He was the CEO of PrimeSense, the creator of the Kinect sensor for Xbox360, PrimeSense was acquired by Apple (NASDAQ: APPL) in 2013. Prior to PrimeSense, Inon served as CEO of DSP Group, (NASDAQ: DSPG). Inon was a Co-Founder and COO of Ceragon Networks Ltd (NASDAQ:CRNT). Prior to Ceragon Networks Inon was VP of the Electronic Research and Development Department of the Israeli Ministry of Defense. Inon holds a BSc and MSc degrees in Electrical Engineering and Electronics from Tel Aviv University.

Eric is the founder and CSO of Kinnate Biopharma (NASDQ: KNTE). With over 20 years of drug discovery experience in small molecule oncology research across academia, CRO, biotech, and large pharma, Eric was previously Global Head of Oncology R&D Strategy and External Innovations at Crown Biosciences prior to its acquisition by JSR. He was also responsible for bringing multiple drugs into clinical testing when he was Director of Discovery Biology at Samumed and a Research Investigator at the Genomics Institute of the Novartis Research Foundation. Eric completed his postdoctoral fellowship at The Scripps Research Institute and holds a BS in biochemistry from the University of California at Davis and a PhD in biological sciences from the University of California at Irvine.

Keith Mostov has been Professor of Cell Biology and Medicine at UCSF since 1989. In 1997 he founded AriZeke Pharmaceuticals, together with Jeff Sollender, a partner at Forward Ventures in San Diego. AriZeke used technology developed in Mostov’s lab and licensed from UCSF for oral delivery of biologicals. More recently, Altschuler and Mostov founded NovellusDx, which is a thriving drug discovery company in the oncology arena. Mostov has also consulted for numerous other companies, such as Millipore-Sigma, Dow Corning, LI-COR, Novartis and Roche. Professor Mostov is the author of more than 160 peer reviewed papers, many in the oncology field, has 8 issued patents and received research funding accumulating to more than $25M

Dr. Emans is a molecular-cell biologist and the founder of a biotech company producing tools for the drug discovery market. Specifically, tools used to perform knock out based assays (CRISPER, siRNA). His key areas of expertise are fund raising, and 5 years as a founder/CSO. His doctoral thesis was performed at the EMBL in Heidelberg, with postdoctoral work in biophysics at UCSF.  Subsequently, he was a principal investigator at the Pasteur Institute before founding Persomics.   He has published more than 40 publications and >20 issued patents